1. Home
  2. LASR vs ARQT Comparison

LASR vs ARQT Comparison

Compare LASR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

HOLD

Current Price

$39.72

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$25.64

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LASR
ARQT
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.5B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
LASR
ARQT
Price
$39.72
$25.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$54.31
$34.00
AVG Volume (30 Days)
1.2M
2.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
62.99
88.79
EPS
N/A
0.03
Revenue
$191,359,000.00
$376,072,000.00
Revenue This Year
$10.91
$34.85
Revenue Next Year
$14.32
$29.39
P/E Ratio
N/A
$887.33
Revenue Growth
38.09
91.34
52 Week Low
$27.79
$16.68
52 Week High
$86.95
$31.77

Technical Indicators

Market Signals
Indicator
LASR
ARQT
Relative Strength Index (RSI) 36.56 53.44
Support Level $38.95 $24.91
Resistance Level $39.32 $27.57
Average True Range (ATR) 1.73 1.12
MACD 0.60 0.32
Stochastic Oscillator 30.83 67.67

Price Performance

Historical Comparison
LASR
ARQT

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: